The non-adjunctive indication allows the use of Dexcom G5 Mobile CGM system as a replacement to fingerstick glucose testing for diabetes treatment decisions.
Diabetes patients and their physicians can take treatment decisions based on data provided by the Dexcom G5 Mobile CGM system, helping to avoid the use of painful fingersticks associated with blood glucose meters.
Featuring Bluetooth technology, the system sends glucose data directly to a smart device, avoiding to carry a separate receiver.
The device transmitter is said to securely send vital glucose information every five minutes directly to an app on iOS-enabled devices for real-time diabetes management.
Users can also select up to five designated recipients or followers to monitor the user's glucose information and receive alert notifications for protection.
The company plans to launch the G5 Mobile CGM system in the first three months of the net year.
Dexcom president and CEO Kevin Sayer said: "The new indication in Canada for the Dexcom G5 Mobile CGM system is an astounding milestone for people with diabetes and is a critical step forward for advancing diabetes technology to drastically change diabetes management.
"Now, people with diabetes in Canada who use the Dexcom G5 Mobile CGM system can make treatment decisions without having to perform multiple fingersticks daily, which has posed a significant barrier to properly managing diabetes in the past."
